IO Therapies in the Advanced Bladder Cancer Clinic: Aligning Your Team for Success

Target Audience
Urology community physicians, physician assistants, nurse practitioners, nurses, and pharmacists.

Statement of Need/Program Overview
As the treatment paradigm for bladder cancer continuously evolves, all members of the oncology healthcare team must be equipped to evolve with it to ensure optimal patient care. With this evolution comes many questions for the bladder cancer treatment team. Join Drs. Neal Shore, Arjun Balar, Lidia Lopez, and Nurse Joanie Pfahl as they examine the new paradigm of bladder treatment using ICIs, and discuss the important role of each person on the treatment team.

Consider the evolving roles of ICIs in multimodal and/or combination regimens, including use earlier in the disease course in BCG-unresponsive disease.

Learning Objectives
Upon completion of this activity, participants should be better able to:

Consider the evolving roles of ICIs in multimodal and/or combination regimens, including use earlier in the disease course in BCG-unresponsive disease.
Incorporate available patient education for immunotherapies used in UBC, including education on immune-related adverse events and role of the interprofessional bladder cancer team.